Look for any podcast host, guest or anyone
Showing episodes and shows of

Touchpodcast

Shows

touchPODCASTtouchPODCASTExpanding horizons for patients with Pompe disease: Using data to guide clinical practicetouchCONGRESS for touchCARDIO Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview       Data reviews with Prof. Mozaffar,       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on lon...2025-03-181h 06touchPODCASTtouchPODCASTMDT perspectives on the importance of patient engagement in PARPi use - Video 3touchMDT for touchONCOLOGY Listen to experts Dr Alicia Morgans, Dr Grace Cullen, and patient advocate, Mr Tony Collier, discuss the importance and practicalities of engaging patients in their care and hear insights from the perspective of a patient advocate in relation to the use of PARP inhibitors. The multidisciplinary team and patient advocate: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA Patient Advocate – Mr Tony Collier Tackle Prostate Cancer...2025-03-0613 mintouchPODCASTtouchPODCASTMDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2touchMDT for touchONCOLOGY   Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.   The multidisciplinary team: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA Pathologist – Prof. Albrecht Stenzinger University of Heidelberg, Heidelberg, Germany This touchPODCAST is for HCPs outside of the UK  only. This activi...2025-03-0613 mintouchPODCASTtouchPODCASTMDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1touchMDT for touchONCOLOGY MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC). The multidisciplinary team: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA This touchPODCAST is for HCPs outside of the UK  only. This activ...2025-03-0613 mintouchPODCASTtouchPODCASTThe next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGYtouchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D). The experts Dr Sue Pedersen, University of Calgary, Calgary, Canada Prof. Carel le Roux, University College Dublin, Dublin, Ireland Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA This touchPODCAST is for healthcare professionals outside of...2025-02-2732 mintouchPODCASTtouchPODCASTThe next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIOtouchEXPERT OPINIONS for touchCARDIO Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D). The experts Dr Sue Pedersen, University of Calgary, Calgary, Canada Prof. Carel le Roux, University College Dublin, Dublin, Ireland Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA This touchPODCAST is for healthcare professionals outside of...2025-02-2732 mintouchPODCASTtouchPODCASTFrom clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancertouchEXPERT OPINIONS for touchONCOLOGY Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations.   The experts Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany Dr Sonia Pernas: Cat...2025-02-2136 mintouchPODCASTtouchPODCASTCervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individualstouchIN CONVERSATION for touchINFECTIOUS DISEASES Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings. The experts Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA Dr Marc Steben, HPV Global Action and Université de Montréal, Canada This touchPODCAST is for HCPs outside of th...2025-02-2036 mintouchPODCASTtouchPODCASTCervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individualstouchIN CONVERSATION for touchONCOLOGY Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings. The experts Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA Dr Marc Steben, HPV Global Action and Université de Montréal, Canada This touchPODCAST is for HCPs outside of the UK...2025-02-2036 mintouchPODCASTtouchPODCASTLooking to the future in the treatment of steroid-refractory chronic GvHDtouchFOCUS for touchHAEMATOLOGY In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies. The expert: Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK.  This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchHAEMATOLOGY.com 2025-02-1816 mintouchPODCASTtouchPODCASTLooking to the future in the treatment of steroid-refractory chronic GvHDtouchFOCUS for touchONCOLOGY In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies. The expert: Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK.  This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchoncology.com 2025-02-1816 mintouchPODCASTtouchPODCASTUpdates in BCMA-directed therapies in multiple myeloma from ASH 2024touchCONGRESS for ONCOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice.  The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCP...2025-02-0655 mintouchPODCASTtouchPODCASTUpdates in BCMA-directed therapies in multiple myeloma from ASH 2024touchCONGRESS for touchHAEMATOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice.  The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCP...2025-02-0655 mintouchPODCASTtouchPODCASTRAS mutations and personalized cancer care: Targeting the futuretouchEXPERT OPINIONS for touchONCOLOGY Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes. The experts Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Th...2025-01-3031 mintouchPODCASTtouchPODCASTWhat’s new in primary ITP? Key updates from ASH 2024touchPANEL DISCUSSION for touchONCOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.   The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only...2025-01-2940 mintouchPODCASTtouchPODCASTWhat’s new in primary ITP? Key updates from ASH 2024touchPANEL DISCUSSION for touchHAEMATOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.   The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only...2025-01-2940 mintouchPODCASTtouchPODCASTFocused insights: Data implications of ADCs in NSCLC treatmenttouchFOCUS for touchRESPIRATORY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only. This activity is funded by an independent medical education gr...2025-01-2421 mintouchPODCASTtouchPODCASTFocused insights: Data implications of ADCs in NSCLC treatmenttouchFOCUS for touchONCOLOGY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only This activity is funded by an independent medical education gr...2025-01-2421 mintouchPODCASTtouchPODCASTCollaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGYtouchSYMPOSIUM for touchHAEMATOLOGY Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA.  Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies. Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life  Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current man...2025-01-211h 20touchPODCASTtouchPODCASTCollaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchHAEMATOLOGYtouchSYMPOSIUM for touchHAEMATOLOGY Listen to this touchSYMPOSIUM recorded live in December 2024 preceding the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, USA.  Symposium chair Prof. Cindy Neunert is joined by Dr María Eva Mingot Castellano and Prof. David Kuter to discuss the impact of immune thrombocytopenia (ITP) on patients and review current and emerging treatment strategies. Session 1: Prof. Cindy Neunert considers how ITP affects patients' lives, including the impact on health-related quality of life  Session 2: Dr Mingot Castellano discusses two illustrative patient cases and the application of current man...2025-01-211h 20touchPODCASTtouchPODCASTManagement of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGYtouchEXPERT FOCUS for touchONCOLOGY Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered. The experts Dr AeRang Kim, Children's National Hospital, Washington, DC, USA Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK. 2025-01-0637 mintouchPODCASTtouchPODCASTManagement of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGYtouchEXPERT FOCUS for touchNEUROLOGY Listen to three experts provide insights into the optimal management of neurofibromatosis type 1 (NF1) in paediatric and adult patients, with a focus on plexiform neurofibromas (PNs). Strategies for ensuring the smooth transitioning of paediatric patients into the adult care system are also considered. The experts Dr AeRang Kim, Children's National Hospital, Washington, DC, USA Dr Rebecca Brown, University of Alabama School of Medicine, Birmingham, AL, USA Dr Kaleb Yohay, NYU Langone Health, New York, NY, USA This touchPODCAST is for healthcare professionals outside of the UK. 2025-01-0637 mintouchPODCASTtouchPODCASTAdvancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative settingtouchEXPERT OPINIONS for touchONCOLOGY Listen to an oncologist, urologist and oncology nurse highlight the key data for immunotherapy in the perioperative setting for muscle-invasive bladder cancer, practical considerations for its use in clinical practice, and how possible side effects can be monitored for and managed. They also consider the role of the multidisciplinary team in implementing this treatment modality. The experts Dr Laura Mertens, Netherlands Cancer Institute, Amsterdam, The Netherlands Prof. Thomas Powles, Barts Cancer Centre, London, UK Ms Lindsay Diamond, Icahn School of Medicine at Mount Sinai, New York, NY, USA This...2024-12-1938 mintouchPODCASTtouchPODCASTNavigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGYtouchEXPERT OPINIONS for touchDERMATOLOGY Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions. The experts Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Dr Teresa Amaral, Tübingen University, Tübingen, Germany This touchPODCAST is for healthcare professionals outside of the UK only This activity is funded by an in...2024-12-1734 mintouchPODCASTtouchPODCASTNavigating treatment choices in high-risk early-stage melanoma - touchONCOLOGYtouchEXPERT OPINIONS for touchONCOLOGY  Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions. The experts Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Dr Teresa Amaral, Tübingen University, Tübingen, Germany This touchPODCAST is for healthcare professionals outside of the UK only This activity is funded by an ind...2024-12-1734 mintouchPODCASTtouchPODCASTAdvances in IOL technology and power calculations: Updates and innovations from 2024touchFOCUS for touchOPHTHALMOLOGY Listen to Dr John Ladas, an expert in cataract surgery, as he answers a series of questions on intraocular lens power calculation, including how the use of artificial intelligence may help to improve accuracy, and provides an update on the latest advances in intraocular lens technology. The expert Dr John Ladas, Maryland Eye Consultants & Surgeons, Silver Spring, MD, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Johnson & Johnson Surgical Vision, Inc. and Carl Zeiss Meditec, Inc. This activity...2024-12-0413 mintouchPODCASTtouchPODCASTSupporting healing in epidermolysis bullosa: Innovations and new directions for caretouchFOCUS for touchDERMATOLOGY Listen to Prof. Amy Paller as she answers a series of questions on the key features of epidermolysis bullosa, including its pathophysiology and clinical manifestations. In addition, she responds to questions on the role of new and emerging topical therapies for epidermolysis bullosa in patient care, with a focus on a multidisciplinary team approach. The expert: Prof. Amy Paller - Northwestern University Feinberg School of Medicine, Chicago, IL, USA This touchPODCAST is for HCPs outside the UK.  This activity is funded by an independent medical education grant f...2024-11-2718 mintouchPODCASTtouchPODCASTPrimary biliary cholangitis: Appraising the changing therapeutic landscapetouchEXPERT OPINIONS for touchIMMUNOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.  The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchimmunologyime.org/Primary-biliary-cholangitis-therapeutic-landscape 2024-11-1435 mintouchPODCASTtouchPODCASTPrimary biliary cholangitis: Appraising the changing therapeutic landscapetouchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.  The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchendocrinologyime.org/primary-biliary-cholangitis-therapeutic-landscape 2024-11-1435 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-11-1413 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-11-1416 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-11-1413 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-11-1416 mintouchPODCASTtouchPODCASTtouchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?touchMDT for touchRESPIRATORY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects. The multidisciplinary team Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Nethe...2024-11-1315 mintouchPODCASTtouchPODCASTtouchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?touchMDT for touchRESPIRATORY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the...2024-11-1313 mintouchPODCASTtouchPODCASTtouchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?touchMDT for touchRESPIRATORY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC. The multidisciplinary team: Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This...2024-11-1314 mintouchPODCASTtouchPODCASTtouchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?touchMDT for touchONCOLOGY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects. The multidisciplinary team Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Nethe...2024-11-1315 mintouchPODCASTtouchPODCASTtouchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?touchMDT for touchONCOLOGY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the...2024-11-1313 mintouchPODCASTtouchPODCASTtouchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?touchMDT for touchONCOLOGY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC. The multidisciplinary team: Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This...2024-11-1314 mintouchPODCASTtouchPODCASTVaccination strategies for pneumococcal diseasetouchEXPERT OPINIONS for touchINFECTIOUS DISEASES In this activity, Prof. Antoni Torres, a leading expert in respiratory infections, discusses the burden of pneumococcal disease in vulnerable patient populations, the evolving landscape of Streptococcus pneumoniae subtypes and the role that next-generation vaccines can play in preventing severe pneumococcal infections. The expert Prof. Antoni Torres, University of Barcelona, Spain This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck Sharp & Dohme LLC. This activity is jointly provided by USF H...2024-11-0533 mintouchPODCASTtouchPODCASTOptimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024touchCONGRESS for touchONCOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the...2024-10-2852 mintouchPODCASTtouchPODCASTOptimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024touchCONGRESS for touchHAEMATOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the...2024-10-2852 mintouchPODCASTtouchPODCASTPharmacological management of agitation in Alzheimer's dementiatouchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology.  The experts Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA  Prof. Krista Lanctôt, University of Toronto, ON, Canada  Prof. James Galvin, University of Miami, FL, USA    This touchPODCAST is for HCPs outside of the UK only.  This activity is funded by an independent medical education grant from Lundbeck. This activity...2024-10-2434 mintouchPODCASTtouchPODCASTtouchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIOtouchIN CONVERSATION for touchCARDIO Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape.  This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. Th...2024-10-2435 mintouchPODCASTtouchPODCASTtouchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORYtouchIN CONVERSATION for touchRESPIRATORY Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape.  This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. Th...2024-10-2435 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-10-1614 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-10-1615 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-10-1614 mintouchPODCASTtouchPODCASTtouchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK...2024-10-1615 mintouchPODCASTtouchPODCASTTargets in early NSCLC: A focus on EGFR-mutant treatment optionstouchFOCUS for touchONCOLOGY Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testing and the importance of multidisciplinary care for optimizing outcomes in these patients. The expert Dr Jennifer Carlisle, Winship Cancer Institute of Emory University, Atlanta, GA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical...2024-10-1516 mintouchPODCASTtouchPODCASTTargeting BCMA in multiple myeloma: Insights from COMy and EHA 2024touchCONGRESS for touchONCOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice. Overview       Data reviews with Prof. Mateos,       Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below Clinical themes Approved indications for BCMA-targeting agents, New app...2024-10-0757 mintouchPODCASTtouchPODCASTTargeting BCMA in multiple myeloma: Insights from COMy and EHA 2024touchCONGRESS for touchHAEMATOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice. Overview       Data reviews with Prof. Mateos,       Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below Clinical themes Approved indications for BCMA-targeting agents, New app...2024-10-0757 mintouchPODCASTtouchPODCASTInnovations in glaucoma care: Targeting pathophysiology to expand treatment optionstouchEXPERT OPINIONS for touchOPHTHALMOLOGY Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice. The experts Angelo P Tanna, MD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA Courtney E Bovee, MD - Bovee Eye, Tampa Bay, FL, USA Joseph F Panarelli, MD - NYU Langone Eye Center, New York, NY, USA This touchPODCAST is for HCPs only. This activity is funded by an...2024-10-0733 mintouchPODCASTtouchPODCASTExperts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescentstouchIN CONVERSATION for touchIMMUNOLOGY Listen to Prof. Diamant Thaçi in conversation with Dr Benjamin Ungar. They respond to questions submitted by the HCP audience and provide their expert insights regarding managing moderate–severe atopic dermatitis (AD) in children and adolescents, including assessing the severity of AD, selecting systemic therapy, and managing the potential side effects of systemic treatment. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals and is jointly provided by USF Health and touchIME. F...2024-09-3040 mintouchPODCASTtouchPODCASTExperts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescentstouchIN CONVERSATION for touchDERMATOLOGY Listen to Prof. Diamant Thaçi in conversation with Dr Benjamin Ungar. They respond to questions submitted by the HCP audience and provide their expert insights regarding managing moderate–severe atopic dermatitis (AD) in children and adolescents, including assessing the severity of AD, selecting systemic therapy, and managing the potential side effects of systemic treatment. This touchPODCAST is for HCPs outside of the UK.  This activity is funded by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals and is jointly provided by USF Health and touchIME. Fo...2024-09-3040 mintouchPODCASTtouchPODCASTUpdates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitorstouchFOCUS for touchONCOLOGY Listen to Prof. Barbara Burtness as she answers a series of questions focused on the evolving role of immune checkpoint inhibitors  in the first- and subsequent-line settings for recurrent/metastatic nasopharyngeal carcinoma.  The expert Prof. Barbara Burtness, Yale School of Medicine, New Haven, CT, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Coherus BioSciences. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/touchfocus_ev...2024-09-2618 mintouchPODCASTtouchPODCASTtouchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchIMMUNOLOGYtouchMDT for touchIMMUNOLOGY Listen to experts Prof. Sonja Ständer, Ms Michelle Clayton, Prof. Gideon Hirschfield and patient advocate, Mrs Collette Thain MBE, discuss individualizing management strategies for patients with cholestatic pruritus and primary biliary cholangitis (PBC), and the importance of patient education and counselling. The multidisciplinary team and patient advocate: Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany Nurse – Ms Michelle Clayton St James’ University Hospital, Leeds, UK Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada  Patient Advocate – Mrs Collette Th...2024-09-2615 mintouchPODCASTtouchPODCASTtouchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchENDOCRINOLOGYtouchMDT for touchENDOCRINOLOGY Listen to experts Prof. Sonja Ständer, Ms Michelle Clayton, Prof. Gideon Hirschfield and patient advocate, Mrs Collette Thain MBE, discuss individualizing management strategies for patients with cholestatic pruritus and primary biliary cholangitis (PBC), and the importance of patient education and counselling. The multidisciplinary team and patient advocate: Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany Nurse – Ms Michelle Clayton St James’ University Hospital, Leeds, UK Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada  Patient Advocate – Mrs Collette Th...2024-09-2615 mintouchPODCASTtouchPODCASTtouchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchENDOCRINOLOGYtouchMDT for touchENDOCRINOLOGY Listen to experts Ms Michelle Clayton, Prof. Sonja Ständer and Prof. Gideon Hirschfield discuss the importance of assessing for cholestatic pruritus in patients with primary biliary cholangitis (PBC) and review the tools used in clinical practice. The multidisciplinary team: Nurse – Ms Michelle Clayton St James’ University Hospital, Leeds, UK Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada This touchPODCAST is for HCPs outside of the UK and USA only.2024-09-2614 mintouchPODCASTtouchPODCASTtouchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchENDOCRINOLOGYtouchMDT for touchENDOCRINOLOGY Pruritus in PBC and me: The patient experience Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany  Patient Advocate – Mrs Collette Thain MBE PBC Foundation, Edinburgh, UK This touchPODCAST is for HCPs ou...2024-09-2612 mintouchPODCASTtouchPODCASTtouchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchDERMATOLOGYtouchMDT for touchDERMATOLOGY Pruritus in PBC and me: The patient experience Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany  Patient Advocate – Mrs Collette Thain MBE PBC Foundation, Edinburgh, UK This touchPODCAST is for HCPs ou...2024-09-2612 mintouchPODCASTtouchPODCASTtouchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchDERMATOLOGYtouchMDT for touchDERMATOLOGY Listen to experts Ms Michelle Clayton, Prof. Sonja Ständer and Prof. Gideon Hirschfield discuss the importance of assessing for cholestatic pruritus in patients with primary biliary cholangitis (PBC) and review the tools used in clinical practice. The multidisciplinary team: Nurse – Ms Michelle Clayton St James’ University Hospital, Leeds, UK Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada This touchPODCAST is for HCPs outside of the UK and USA only.2024-09-2614 mintouchPODCASTtouchPODCASTtouchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchDERMATOLOGYtouchMDT for touchDERMATOLOGY Listen to experts Prof. Sonja Ständer, Ms Michelle Clayton, Prof. Gideon Hirschfield and patient advocate, Mrs Collette Thain MBE, discuss individualizing management strategies for patients with cholestatic pruritus and primary biliary cholangitis (PBC), and the importance of patient education and counselling. The multidisciplinary team and patient advocate: Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany Nurse – Ms Michelle Clayton St James’ University Hospital, Leeds, UK Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada  Patient Advocate – Mrs Collette Th...2024-09-2615 mintouchPODCASTtouchPODCASTtouchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchIMMUNOLOGYtouchMDT for touchIMMUNOLOGY Listen to experts Ms Michelle Clayton, Prof. Sonja Ständer and Prof. Gideon Hirschfield discuss the importance of assessing for cholestatic pruritus in patients with primary biliary cholangitis (PBC) and review the tools used in clinical practice. The multidisciplinary team: Nurse – Ms Michelle Clayton St James’ University Hospital, Leeds, UK Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada This touchPODCAST is for HCPs outside of the UK and USA only.2024-09-2614 mintouchPODCASTtouchPODCASTtouchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchIMMUNOLOGYtouchMDT for touchIMMUNOLOGY Pruritus in PBC and me: The patient experience Listen to experts Prof. Gideon Hirschfield and Prof. Sonja Ständer, plus patient advocate Mrs Collette Thain MBE, explore the burden of cholestatic pruritus in patients with primary biliary cholangitis (PBC). The multidisciplinary team and patient advocate: Hepatologist – Prof. Gideon Hirschfield University of Toronto, Toronto, Canada Dermatologist – Prof. Sonja Ständer University of Münster, Münster, Germany  Patient Advocate – Mrs Collette Thain MBE PBC Foundation, Edinburgh, UK This touchPODCAST is for HCPs ou...2024-09-2612 mintouchPODCASTtouchPODCASTPerspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease - touchRESPIRATORYtouchCLINICAL PERSPECTIVES for touchRESPIRATORY Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey. Course director Dr Helena Yu, Memorial Sloan Kettering Cancer...2024-09-251h 43touchPODCASTtouchPODCASTPerspectives on EGFR-mutant and wildtype NSCLC Tailoring treatment advances in late-stage disease - touchONCOLOGYtouchCLINICAL PERSPECTIVES for touchONCOLOGY Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey. Course director Dr Helena Yu, Memorial Sloan Kettering Cancer Center New...2024-09-251h 43touchPODCASTtouchPODCASTExpanding HER2 horizons: Implications for NSCLC and beyondtouchPANEL DISCUSSION for touchRESPIRATORY Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.   The experts Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA This touchPODCAST is for HCPs outside of the UK on...2024-09-2541 mintouchPODCASTtouchPODCASTExpanding HER2 horizons: Implications for NSCLC and beyondtouchPANEL DISCUSSION for touchONCOLOGY Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.   The experts Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA This touchPODCAST is for HCPs outside of the UK on...2024-09-2541 mintouchPODCASTtouchPODCASTInsights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?touchCONGRESS for touchONCOLOGY Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice. Overview  Data reviews with Dr McDonald Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below Clinical themes How does IT...2024-09-0553 mintouchPODCASTtouchPODCASTInsights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?touchCONGRESS for touchHAEMATOLOGY Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice. Overview  Data reviews with Dr McDonald Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below Clinical themes How does IT...2024-09-0553 mintouchPODCASTtouchPODCASTContinuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomestouchPANEL DISCUSSION for touchENDOCRINOLOGY Listen to a panel of experts discuss the benefits of CGM in patients with T2D, strategies to overcome the barriers to its uptake and how to best support patients in implementing CGM. The experts Prof. Stewart Harris, Western University,  London, Ontario, Canada, Dr Anders Carlson, International Diabetes Center at Park Nicollet, Minneapolis, MN, USA, Prof. Shannon Idzik, University of Maryland School of Nursing, Baltimore, MD, USA This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education g...2024-08-2941 mintouchPODCASTtouchPODCASTPersonalizing care within the MDT for patients with early through to advanced RCCtouchFOCUS for touchONCOLOGY Listen to Prof. Hans Hammers as he answers a series of questions on the application of prognostic markers and clinical data within the multidisciplinary team to personalize care for patients with early stage through to advanced and metastatic RCC. In addition, he responds to questions on the use of effective communication strategies and shared decision-making when managing diverse and/or underserved populations with RCC. The expert Prof. Hans Hammers, UT Southwestern, Dallas, TX, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical...2024-08-1919 mintouchPODCASTtouchPODCASTSelecting ART: Working with people living with HIV to find the best regimentouchIN CONVERSATION for touchINFECTIOUS DISEASES Listen to a conversation between Dr Christoph Boesecke and Dr Tristan Barber, two experts on HIV practising in Germany and the UK. They respond to questions submitted by the HCP audience and provide their insights on best practices for antiretroviral therapy selection for people living with HIV. The experts Dr Christoph Boesecke – University of Bonn, Bonn, Germany Dr Tristan Barber – Royal Free London NHS Foundation Trust, London, UK This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical educ...2024-08-1539 mintouchPODCASTtouchPODCASTThyroid eye disease: An evolving continuum of caretouchPANEL DISCUSSION for touchOPHTHALMOLOGY Listen to a panel of leading experts discuss thyroid eye disease, including the underlying mechanisms, risk factors, symptomatology and burden of disease in affected patients, as well as the process for screening and diagnosing the disease. The experts Dr Andrea Kossler, Stanford University School of Medicine, Palo Alto, CA, USA Dr Mario Salvi, University of Milan, Milan, Italy Dr Edsel Ing, University of Alberta, Edmonton and University of Toronto, Ontario, Canada This touchPODCAST is for HCPs only.  This activity is funded by an independent medical education grant f...2024-08-0838 mintouchPODCASTtouchPODCASTThyroid eye disease: An evolving continuum of caretouchPANEL DISCUSSION for touchENDOCRINOLOGY Listen to a panel of leading experts discuss thyroid eye disease, including the underlying mechanisms, risk factors, symptomatology and burden of disease in affected patients, as well as the process for screening and diagnosing the disease.  The experts Dr Andrea Kossler, Stanford University School of Medicine, Palo Alto, CA, USA Dr Mario Salvi, University of Milan, Milan, Italy Dr Edsel Ing, University of Alberta, Edmonton and University of Toronto, Ontario, Canada This touchPODCAST is for HCPs only.  This activity is funded by an independent medical education grant fr...2024-08-0838 mintouchPODCASTtouchPODCASTIntracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategiestouchTALKS for touchNEUROLOGY A thrombosis and haemostasis expert shares insights into reversal strategies for patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH), including benefits and risks of DOAC use, evidence for DOAC reversal agents and guideline-directed management of the condition.  The expert Prof. Dr. med. Jan Beyer-Westendorf, University Hospital Carl Gustav Carus, Dresden, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information v...2024-08-0547 mintouchPODCASTtouchPODCASTIntracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategiestouchTALKS for touchCARDIO A thrombosis and haemostasis expert shares insights into reversal strategies for patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH), including benefits and risks of DOAC use, evidence for DOAC reversal agents and guideline-directed management of the condition.  The expert Prof. Dr. med. Jan Beyer-Westendorf, University Hospital Carl Gustav Carus, Dresden, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information v...2024-08-0547 mintouchPODCASTtouchPODCASTExpanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approachestouchFOCUS for touchONCOLOGY   Listen to Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment across various cancer types. The expert Dr Dana Chase - UCLA Health, Los Angeles, CA, USA   This touchPODCAST is for HCPs only.   This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.    For further information visit our website: https://touchoncologyime.org/ 2024-08-0216 mintouchPODCASTtouchPODCASTThe path from detection to personalized long-term care for Fabry diseasetouchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to three leading Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions. The experts Prof. Aleš Linhart, Charles University and General University Hospital, Prague, Czech Republic Dr Eric Wallace, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA Prof. William Wilcox, Emory University School of Medicine, Atlanta, GA, USA This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided b...2024-07-3136 mintouchPODCASTtouchPODCASTThe path from detection to personalized long-term care for Fabry diseasetouchEXPERT OPINIONS for touchCARDIO Listen to three leading Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions. The experts Prof. Aleš Linhart, Charles University and General University Hospital, Prague, Czech Republic Dr Eric Wallace, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA Prof. William Wilcox, Emory University School of Medicine, Atlanta, GA, USA This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided b...2024-07-3136 mintouchPODCASTtouchPODCASTThe path from detection to personalized long-term care for Fabry diseasetouchEXPERT OPINIONS for touchNEUROLOGY Listen to three leading Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions. The experts Prof. Aleš Linhart, Charles University and General University Hospital, Prague, Czech Republic Dr Eric Wallace, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA Prof. William Wilcox, Emory University School of Medicine, Atlanta, GA, USA This touchPODCAST is for healthcare professionals outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided b...2024-07-3136 mintouchPODCASTtouchPODCASTEmerging data with immunotherapy in ESCC and potential impact for clinical practicetouchTALKS for touchONCOLOLOGY Listen to a leading expert discussing the recent developments in esophageal cancer with a primary focus on esophageal squamous cell carcinoma (ESCC)  The expert: Dr Elizabeth Smyth, Addenbrooke’s Hospital, Cambridge, UK Overview: Part 1: Insights from 2021 (0:00) Part 2: Insights from ASCO and ESMO GI 2022 (13:29) Part 3: Insights from the updated ESMO Clinical Practice Guideline (24:08) Part 4: Insights from ESMO Asia 2022 and ASCO GI 2023 (34:53) This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an independent medical education grant from Novartis. This activity is...2023-03-0946 mintouchPODCASTtouchPODCASTManaging disease progression: Considerations for treatment selection and sequencingtouchMDT for touchRESPIRATORY Listen to leading specialists from the MDT discuss the role of monitoring in identifying disease progression, and review the current and emerging treatment options for a patient with a pancreatic NET. The multidisciplinary team and patient Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany Nurse specialist: Catherine Bouvier Ellis, UK This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications.  This activity is jointly provided by US...2022-09-2712 mintouchPODCASTtouchPODCASTSupporting treatment adherence: What strategies are needed for safety management?touchMDT for touchRESPIRATORY Listen to leading specialists from the MDT discuss the side effects associated with treatment in a patient with liver-dominant disease and the importance of addressing patient needs in ensuring adherence to treatment.   The multidisciplinary team and patient Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Nurse specialist: Catherine Bouvier Ellis, UK This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications.  This activity is jointly provided by USF Health and touchIME. 2022-09-2711 mintouchPODCASTtouchPODCASTMapping an individualized treatment plan: What role does the MDT play?touchMDT for touchRESPIRATORY Listen to leading specialists from the MDT discuss the importance of a coordinated approach to clinical decision making in a patient with a lung NET. The multidisciplinary team  Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications.  This activity is jointly provided by USF Health and touchIME. For further information visit our website: htt...2022-09-2712 mintouchPODCASTtouchPODCASTAchieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?touchMDT for touchRESPIRATORY Listen to leading specialists from the MDT discuss the diagnostic workup and challenges associated with diagnosing rare and unusual NETs. The multidisciplinary team Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/mdt-management-nets/  2022-09-2714 mintouchPODCASTtouchPODCASTManaging disease progression: Considerations for treatment selection and sequencingtouchMDT for touchONCOLOGY Listen to leading specialists from the MDT discuss the role of monitoring in identifying disease progression, and review the current and emerging treatment options for a patient with a pancreatic NET. The multidisciplinary team and patient Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany Nurse specialist: Catherine Bouvier Ellis, UK This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This activity is jointly provided by U...2022-09-2712 mintouchPODCASTtouchPODCASTSupporting treatment adherence: What strategies are needed for safety management?touchMDT for touchONCOLOGY Listen to leading specialists from the MDT discuss the side effects associated with treatment in a patient with liver-dominant disease and the importance of addressing patient needs in ensuring adherence to treatment.   The multidisciplinary team and patient Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Nurse specialist: Catherine Bouvier Ellis, UK This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This activity is jointly provided by USF Health and touchIME. For...2022-09-2711 mintouchPODCASTtouchPODCASTMapping an individualized treatment plan: What role does the MDT play?Mapping an individualized treatment plan: What role does the MDT play? Listen to leading specialists from the MDT discuss the importance of a coordinated approach to clinical decision making in a patient with a lung NET. The multidisciplinary team  Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This medical education is jointly provided by USF Health and touchIME. ...2022-09-2712 mintouchPODCASTtouchPODCASTAchieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?touchMDT for touchONCOLOGY   Listen to leading specialists from the MDT discuss the diagnostic workup and challenges associated with diagnosing rare and unusual NETs.   The multidisciplinary team Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany   This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touc...2022-09-2714 mintouchPODCASTtouchPODCASTManaging disease progression: Considerations for treatment selection and sequencingtouchMDT for touchENDOCRINOLOGY Listen to leading specialists from the MDT discuss the role of monitoring in identifying disease progression, and review the current and emerging treatment options for a patient with a pancreatic NET.   The multidisciplinary team and patient Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany Nurse specialist: Catherine Bouvier Ellis, UK   This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This activity is...2022-09-2712 mintouchPODCASTtouchPODCASTSupporting treatment adherence: What strategies are needed for safety management?touchMDT for touchENDOCRINOLOGY   Listen to leading specialists from the MDT discuss the side effects associated with treatment in a patient with liver-dominant disease and the importance of addressing patient needs in ensuring adherence to treatment.     The multidisciplinary team and patient Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Nurse specialist: Catherine Bouvier Ellis, UK   This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This activity is jointly provided by USF He...2022-09-2711 mintouchPODCASTtouchPODCASTMapping an individualized treatment plan: What role does the MDT play?touchMDT for touchENDOCRINOLOGY   Listen to leading specialists from the MDT discuss the importance of a coordinated approach to clinical decision making in a patient with a lung NET.   The multidisciplinary team  Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany   This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications. This activity is jointly provided by USF Health and touchIME. For further infor...2022-09-2712 mintouchPODCASTtouchPODCASTAchieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?touchMDT for touchENDOCRINOLOGY   Listen to leading specialists from the MDT discuss the diagnostic workup and challenges associated with diagnosing rare and unusual NETs.   The multidisciplinary team Medical oncologist: Dr Diane Reidy-Lagunes, USA Nuclear medicine physician: Dr Thomas Hope, USA Endocrinologist: Prof. Dr med. Marianne Pavel, Germany   This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent medical educational grant from Advanced Accelerator Applications.  This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touc...2022-09-2714 mintouchPODCASTtouchPODCASTAchieving sustained outcomes for moderate-to-severe atopic dermatitistouchTALKS for touchIMMUNOLOGY This touchPODCAST is presented by Dr Melinda Gooderham, SKiN Centre for Dermatology, Peterborough, Ontario, Canada. Listen to Dr Gooderham present the latest data and future directions of systemic therapy for moderate-to-severe atopic dermatitis and how effective treatment can achieve sustained control of symptoms and improve the quality of life of patients and their families. This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is jointly provided by USF Health and touchIME. ...2021-11-3038 mintouchPODCASTtouchPODCASTPatient education, evidence-based treatment and biomarkers in HFrEFtouchPANEL DISCUSSION for touchCARDIO Listen to leading experts discuss how patients can be best supported following a diagnosis of HFrEF, how to implement evidence-based therapies into practice including the potential impact of emerging therapies on treatment selection, and the role of biomarkers in diagnosing, monitoring and determining treatment course for individuals with HFrEF. The experts Prof. Piotr Ponikowski, Wrocław Medical University, Wrocław, Poland Prof. Adriaan A Voors, University Medical Centre Groningen, Groningen, The Netherlands Dr Stephen Greene, Duke University, Durham, NC, USA This touchPODCAST is for HCPs only. Fu...2021-07-2935 mintouchPODCASTtouchPODCASTHighlights from EHA2021 Virtual 2021: Focus on MDS and AMLtouchCONGRESS for touchONCOLOGY Listen to Prof. Uwe Platzbecker (Germany) cover key data presented at EHA2021 Virtual on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML, including expert insights and interpretation from Prof. Valeria Santini (Italy) and Prof. Andrew Wei (Australia). This touchPODCAST is for HCPs only. Funding for this touchPODCAST is from an unrestricted independent educational grant from Novartis. The content was led by touchIME.     For further information visit our website: https://touchoncologyime.org/MDS-AML-EHA2021-touchcongress/ 2021-07-201h 04touchPODCASTtouchPODCASTHighlights from SABCS 2020 VirtualtouchCONGRESS for touchONCOLOGY Listen to key highlights from SABCS Virtual 2020.  This touchPODCAST is presented by Prof. Dr Nadia Harbeck.   We specifically focus on data presented at this congress describing CDK4/6 inhibitors in HR+/HER2- breast cancer and what these data could mean for clinical practice.  This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from Eli Lilly.  This activity is provided by touchIME. For further information visit our website: https://touchoncologyime.org/hrher2-breastcancersabcs2020touchcongress/ 2021-01-181h 06touchPODCASTtouchPODCASTHighlights from ESMO 2020 VirtualtouchCONGRESS for touchONCOLOGY Listen to key highlights from ESMO Virtual 2020. This touchPODCAST is presented by Dr Catherine Kelly.  We specifically focus on data presented at this congress describing CDK4/6 inhibitors in HR+/HER2- breast cancer and what these data could mean for clinical practice.  This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical educational grant from Eli Lilly. This activity is provided by touchIME. For further information visit our website: https://touchoncologyime.org/hrher2-breastcanceresmo2020touchcongress/ 2021-01-141h 03